Serum adiponectin and ghrelin in polycystic ovarian syndrome and its correlation with insulin resistance

https://doi.org/10.53730/ijhs.v6nS7.12507

Authors

  • Dunia M. Mohammed Ali Department of Biochemistry, College of Medicine, University of Kufa, Iraq
  • Suhaer Zeki Al-Fadhel Department of Clinical Laboratory Science, College of Pharmacy, University of Kufa, Iraq Tel: 07803040685
  • Nibras H. Abdulsada Al-Ghuraibawi Department of Pharmacology, College of Pharmacy, University of Kufa, Iraq

Keywords:

Polycystic ovarian syndrome, Adiponectin, Ghrelin, Insulin resistance

Abstract

Background: Polycystic ovarian syndrome (PCOS) considered one of the main complex and heterogeneous endocrine syndromes of females in the pregnancy age , it is commonly accompanied by insulin resistance (IR). Current study aimed to compare adiponectin and ghrelin levels between females with PCOS and healthy females, also inspect the association between ghrelin and adiponectin levels in addition to predict their use as diagnostic factors for the disease, finally to study the connection between adiponectin and ghrelin with lipid profiles and IR in PCOS females . Subjects and Methods: The present case-control study involved 120 females; 60 with PCOS and 60 age-matched healthy controls. Fasting serum levels of glucose, lipid profiles, insulin, adiponectin, ghrelin, follicle stimulating hormone (FSH), luteinizing hormone (LH), testosterone and sex hormone-binding globulin (SHBG), were assessed. Insulin resistance was assessed by homeostasis model assessment (HOMA-IR) and body mass index (BMI) also estimated. The statistical analysis of the data were done by using SPSS 22 . Results: The findings revealed that serum adiponectin level elevated significantly in females with PCOS as compared with control, while ghrelin level decreased significantly in females with PCOS in compared to control. 

Downloads

Download data is not yet available.

References

-Azziz R, Woods, Regna R, et al. The prevalence and features of polycystic ovary syndrome in an unselected population. Journal of clinical Endocrinol and metab. 2004; 89: 2745-2749.

-Pederson SD, Brar S, et al. Polycystic ovary syndrome: validated questionnaire for use in diagnosis. Canadian Family Physician Medicine Family Canadian. 2007; 53(6): 1041-1047.

-Alvarez-Blasco F, Boltella-Carrettero J, San Millan J, Escorbar-Morreale H. Prevelance in overweight and obese females. Arch Inter Med. 2006; 166: 2081-2086.

-Zulian E, Sartorato P, Benedini S, Baro G, Armanini D, Mantero F, Scaroni C. Spironolactone in the treatment of polycystic ovary syndrome: effects on clinical features, insulin sensitivity and lipid profile. J Endocrinol Invest. 2005; 28: 49-55.

-Guilherme A, Virbasius J, gech M. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol. Cell Biol. 2008; 9(7): 367-373.

-Trayhurn P, Wood I. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr. 2004; 92: 347-355.

-Hauner H. Secretary factors from human adipose tissue and their functional role. Proc Nutr Soc. 2005; 64: 163-169.

-Vanky E, Zahlsen K, Spigset O, and Carlsen S. Placental passage of Metformin in females with polycystic ovary syndrome. Fertil Steril. 2005; 83: 1575-1578.

-Krentz AJ, Von Muhlen D, Barrett-Connor E. Adipocytokines, sex hormones, and cardiovascular risk factors in postmenopausal females: Factor analysis of the Rancho Bernado Study. Hom Metab Res. 2009; 41: 773-777.

-Tschritter O, Fritsche A, Thamer C, Haap M, Shirkavand F, Rahe S, et al. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes. 2003; 52: 239-243.

-Kim YA, Noh JH, Kim DJ, Um TH, Cho CR, Jang NY, et al. Serum adiponectin. TNF-alpha, 1L-6 and insulin resistance in females with polycystic ovary syndrome. J Korean Diabetes Assoc. 2006; 30: 104-111.

-Olszanecka-Glinianowicz M, Kuglin D, Dabkowska-Huc A, Skalba P. Serum adiponectin and resistein in relation to insulin resistance and markers of hyperadrogenism in lean and obese females with polycystic ovary syndrome. Eur J Obestet Gynecol Report Biol. 2011; 154: 51-56.

-Delporte C. Structure and physiological actions of ghrelin. Scientific (Cario). 2013: 518909.

-Nog DT, Chan WP, Rajendran S, et al. Dterminants of insulin responsiveness in young females: impact of polycystic ovarian syndrome, nitric oxide, and vitamin D. Nitric Oxide. 2011; 25(3): 326-330.

-The Rotterdam ESHRE/ASRM-Sponsored Consensus Workshop Group, Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS), Hum Reprod, 2004, 19(1): 41-47.

-Calabro P, Yeh E. obesity, inflammation and vascular disease; the role of the adipose tissue as an endocrine organ. Sub Cell. Biochem. 2007; 42: 63-91.

-Teede H, Hutchison S, Zoungas S, Meyer C. Insulin resistance, the metabolic syndrome, diabetes, and cardiovascular disease risk in females with PCOS, Endocrine. 2006; 30: 45-53.

-Lipa G, Sengupta A, Karsies D. PCOS and other androgen excess-related conditions: can changes in dietary intake make a difference ? Nutr Clin Pract. 2008; 23(1): 63-71.

-Blank SK, McCartney CR, Marshall JC. The origins and equal of abnormal neuroendocrine function in polycystic ovary syndrome. Hum Repord. 2006; 12(4): 351-361.

-Cho L, Jayagopal V, Kilpatrick E, Holding S, and Atkin S. The LH/FSH ratio has little use in diagnosing polycystic ovarian syndrome. Ann Clin Biochem. 2006; 13(3): 217-219.

-Hoeger K. Role of lifestyle modification in the management of polycystic ovary syndrome. Best Practice and Rsch Endo and Metab. 2006; 20(2): 293-310.

-Cupisti S, Dittrich R, Binder H. Influence of BMI on measured and calculated androgen parameters in adult females with Hirsutism and PCOS. Exp Clin Endocrinol Diabetes. 2007; 115: 6-38.

-Hulthe J, Hulten LM, Fagerberg B. Low adipocyte-derived plasma protein adiponectin concentrations are associated with the metabolic syndrome and small dense low-density lipoprotein particles: atherosclerosis and insulin resistance study. Metabolism. 2003; 52: 1612-1614.

-Guerre-Millo M. Adiponectin: an update. Diabetes Metab. 2008; 34: 12-18.

-Kusminski I, Mc T, and Kumar O. Role of resistin in obesity, insulin resistance and type II- Diabetes. Clin Sci (Lond). 2005; 109: 243-256.

-Maeda N, Takahashi M, Funahashi T, et al. PPAR gamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 2001; 50: 2094-9.

-Bruun JM, Lihn AS, Verdich C, et al. Regulation of adiponectin by adipose, tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab. 2003; 285: E527-33.

-Ouchi N, Kihara S, Arita Y, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-Kappa B signaling through a cAMP-dependent pathway. Circulation. 2000; 102: 1296-301.

-Wickham EP, Cheang KI, Clore JN, Baillargeon JP, Nestler JE. Total and high-molecular weight adiponectin in females with the polycystic ovary syndrome. Metabolism. 2011; 60: 366-372.

-Yilmaz M, Bukan N, Demirci H, Ozturk C, Kan E, Ayvaz G, et al. Serum resistin and adiponectin levels in females with polycystic ovary syndrome. Gynecol Endocrinol. 2009; 25: 246-252.

-Glintborg D, Andersen M, Hagen C, Frystyk J, Hulstrom V, Flyvbjerg A, et al. Evaluation of metabolic risk markers in polycystic ovary syndrome (PCOS). Adiponectin, ghrelin, leptin and body composition in hirsute PCOS patients and controls. Eur J Endocrinol. 2006; 155(2): 337-345.

-Kamal M, Mohi A, Fawzy M, El-Sawah H. Fasting plasma ghrelin in females with and without PCOS. MEFS J. 2010; 15(2): 91-94.

-Mitkov M, Pehlivanov B, Orbetzova M. Serum ghrelin level in females with polycystic ovary syndrome and its relationship with endocrine and metabolic parameters. Gynecol Endocrinol. 2008; 24(11): 625-630.

-Wasko R, komarowska H, Warenik-Szymankiewicz A, Sowi. Ski. Elevated ghrelin plasma levels in patients with polycystic ovary syndrome. Horm Metab Res. 2004; 36(3): 170-173.

-Daghestani MH, El-Mazny A. Circulating ghrelin levels and the polycystic ovary syndrome: Correlation with the clinical, hormonal and metabolic features. Eur J Obstet Gynecol Repord Biol. 2011; 155(1): 65-68.

-Caminos JE, Tena-Sempere M, Gaytan F, Sanchez-Criado JE, Barreiro MI, Nogueiras R, et al. Expression of ghrelin in the cyclic and pregnant rat ovary. Endocrinology. 2003; 144(4): 1594-1602.

-Tena-Sempere M, Barreiro ML, Gonzalez LC, Gaytan F, Zhang FP, Caminos JE, et al. Novel expression and functional role of ghrelin in rat testis. Endocrinology. 2002; 143(2): 711-725.

-Pagotto U, Gambineri A, Vicennati V, Heiman ML, Tschop M, Pasquali R. Plasma ghrelin, obesity, and the polycystic ovary syndrome: Correlation with insulin resistance and androgen levels. J Clin Endocrinol Metab. 2002; 87(12): 5625-5629.

-Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2022). Post-pandemic health and its sustainability: Educational situation. International Journal of Health Sciences, 6(1), i-v. https://doi.org/10.53730/ijhs.v6n1.5949

Published

05-09-2022

How to Cite

Ali, D. M. M., Al-Fadhel, S. Z., & Al-Ghuraibawi, N. H. A. (2022). Serum adiponectin and ghrelin in polycystic ovarian syndrome and its correlation with insulin resistance. International Journal of Health Sciences, 6(S7), 3439–3448. https://doi.org/10.53730/ijhs.v6nS7.12507

Issue

Section

Peer Review Articles